Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)

Journal of Gastrointestinal Cancer

Volumn 46, Issue 2, 2015, Pages 109-117

  Bodoky, György ^a   Scheulen, Max E ^b   Rivera, Fernando ^c   Jassem, Jacek ^d   Carrato, Alfredo ^e   Moiseyenko, Vladimir ^f   Vynnychenko, Ihor ^g   Prausová, Jana ^h   Van Laethem, Jean Luc ⁱ   Cascinu, Stefano ^j   Ajani, Jaffer A ^k  

^a Szent Laszlo Hospital   (Hungary)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^g SUMY STATE UNIVERSITY   (Ukraine)

^h UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

ⁱ ERASME HOSPITAL   (Belgium)

^j OSPEDALI RIUNITI   (Italy)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Advanced gastric cancer; Cisplatin; FLAGS trial; Patient reported outcomes; Quality of life; S 1

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DRUG COMBINATION; FLUOROURACIL; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG COMBINATION; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMACH NEOPLASMS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG COMBINATIONS; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PROGNOSIS; QUALITY OF LIFE; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; YOUNG ADULT;

EID: 84939460469     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-014-9680-1     Document Type: Article

References (28)

1. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.
2. Cunningham D, Starling N, Rao S, et al. Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.
4. Lordick F, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastr Cancer. 2013;19
5. Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548–57.
6. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53:4004–9.
7. Shirasaka T, Shimamoto Y, Kato T, Fukushima M. Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil. Gan To Kagaku Ryoho. 1998;25:371–84.
8. Blum MA, Suzuki A, Taketa T, Ajani J. The role of S-1 in the treatment of gastric cancer. Gastrointest Cancer Targets Ther. 2011;1:59–67.
9. Chollet P, Schöffski P, Weigang-Köhler K, et al. Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer. 2003;39:1264–70.
10. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34:1715–20.
11. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191–7.
12. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.
13. Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–9.
14. Ajani JA, Lee F-C, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:663–7.
15. Ajani JA, Rodriguez W, Bodoky G. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547–53.
16. Ajani JA, Buyse M, Lichinitser M, et al. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer. 2013. doi:10.1016/j.ejca.2013.07.003.
17. Cella D (1997) Manual of the Functional Assessment of Chronic Illness Therapy (FACIT Scales); Evanston, IL: Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, Version 4
18. Cella D, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–9.
19. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcome. 2003;1:79.
20. Yost K, Hahn E, Cella D. A new measure of chemotherapy convenience and satisfaction. J Clin Oncol. 2005;23(16S):6043.
21. Roderick J, Little R, Rubin D. Statistical analysis with missing data. Hoboken: John Wiley & Sons; 2002.
22. Troxel AB, Fairclough DL, Curran D, et al. Statistical analysis of quality of life with missing data in clinical data in clinical trials. Stat Med. 1998;17:653–66.
23. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32(31):3520–6.
24. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiority trial. Ann Oncol. 2009;20:666–73.
25. Yang J, Min K, Yao Q, Xu CN. S-1–based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis. World J Gastroenterol. 2014;7;20(33):11886–11893.
26. Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA A Cancer J Clin. 2007;57(5):278–300.
27. Bezjak A, Ng P, Skeet R, et al. Oncologists’ use of quality of life information; results of a survey of Eastern Cooperative Oncology Group physicians. Qual Life Res. 2001;10(1):1–13.
28. Garland SN, Pelletier G, Lawe A, et al. Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument. Cancer. 2011;117(6):1302–12.